Mehedi Hasan Bappi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mehedi Hasan Bappi has a total of 162 co-authors. Here are the top co-authors by number of shared publications:
- Muhammad Torequl Islam
Department of Pharmacy Gopalganj Science and Technology University Gopalganj Bangladesh
16 shared publications - Shimul Bhuia
Bioinformatics and Drug Innovation Laboratory BioLuster Research Center Ltd. Gopalganj Bangladesh
11 shared publications - Abdullah Al Shamsh Prottay
Department of Pharmacy, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj 8100, Bangladesh
6 shared publications - Henrique Douglas Melo Coutinho
Regional University of Cariri
6 shared publications Muhammad Torequl Islam
Bioinformatics and Drug Innovation Laboratory BioLuster Research Center Ltd., Gopalaganj Dhaka 8100 Bangladesh
6 shared publicationsShowkoth Akbor
Department of Pharmacy Bangabandhu Sheikh Mujibur Rahman Science and Technology University Gopalganj Bangladesh
6 shared publications
Latest Publications
- 31 July 2026
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (2) , 207
Anti-nociceptive property of thymol: animal study with molecular docking and MD simulation studies
- 31 July 2026
- Published by Springer Nature in In Silico Pharmacology
- Vol. 14 (2) , 207
Anti-nociceptive property of thymol: animal study with molecular docking and MD simulation studies
- Open Access
- 16 July 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (19) , 5975-5991
Therapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus ‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines
Background and Purpose: Aspergillus fumigatus ( A. fumigatus ) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling. This study aimed to elucidate the therapeutic potential of the drug called the Bax inhibitor‐1 antagonist (BIA) and its structural analogues in a murine model of A. fumigatus ‐induced allergic asthma. Experimental Approach: 19 BIA analogues were synthesized and evaluated alongside the original drug BIA in a murine model of A. fumigatus ‐induced airway inflammation. Inflammatory phenotypes were assessed by analysing bronchoalveolar lavage fluid (BALF), lung histopathology, quantification of T‐helper 2 (Th2) and Th17 cytokines. Mechanistic investigations evaluated the AKT/NLRP3 pathway and epithelial‐derived cytokines, while TMBIM6‐mediated ER Ca 2+ flux was monitored using a TMBIM6‐GCaMP3 reporter system. Key Results: BIA and its analogues significantly attenuated inflammatory cell infiltration, goblet cell hyperplasia, airway remodelling and Th2‐associated cytokine expression in the lungs of A. fumigatus ‐challenged mice. BIA and selected analogues also suppressed Th17‐associated cytokine expression. Moreover, BIA analogues preferentially reduced epithelial‐derived cytokine expression. Mechanistically, BIA and select analogues markedly suppressed AKT phosphorylation and NLRP3 expression in lungs and airway epithelial cells. Pharmacological inhibition and TMBIM6 knockdown supported the involvement of the TMBIM6/AKT/NLRP3 signalling axis, while BIA and select analogues inhibited TMBIM6‐mediated ER calcium leakage. Conclusions and Implications: BIA and its analogues attenuate A. fumigatus ‐induced allergic lung inflammation by targeting the TMBIM6/calcium/AKT axis, suppressing NLRP3 signalling and epithelial‐derived inflammatory cytokines. These findings highlight this axis as a promising therapeutic target for fungal‐associated airway inflammation.
- 16 July 2026
- Published by Wiley in British Journal of Pharmacology
- Vol. 183 (19) , 5975-5991
Open AccessTherapeutic potential of a Bax inhibitor‐1/TMBIM6 antagonist (BIA) and its analogues in Aspergillus fumigatus ‐induced asthma via dual targeting of AKT and epithelial‐derived inflammatory cytokines
Background and Purpose: Aspergillus fumigatus ( A. fumigatus ) exposure causes of severe allergic asthma, characterized by airway inflammation and epithelial dysfunction. TMBIM6 (Bax inhibitor‐1) has been implicated in airway epithelial stress responses and AKT signalling. This study aimed to elucidate the therapeutic potential of the drug called the Bax inhibitor‐1 antagonist (BIA) and its structural analogues in a murine model of A. fumigatus ‐induced allergic asthma. Experimental Approach: 19 BIA analogues were synthesized and evaluated alongside the original drug BIA in a murine model of A. fumigatus ‐induced airway inflammation. Inflammatory phenotypes were assessed by analysing bronchoalveolar lavage fluid (BALF), lung histopathology, quantification of T‐helper 2 (Th2) and Th17 cytokines. Mechanistic investigations evaluated the AKT/NLRP3 pathway and epithelial‐derived cytokines, while TMBIM6‐mediated ER Ca 2+ flux was monitored using a TMBIM6‐GCaMP3 reporter system. Key Results: BIA and its analogues significantly attenuated inflammatory cell infiltration, goblet cell hyperplasia, airway remodelling and Th2‐associated cytokine expression in the lungs of A. fumigatus ‐challenged mice. BIA and selected analogues also suppressed Th17‐associated cytokine expression. Moreover, BIA analogues preferentially reduced epithelial‐derived cytokine expression. Mechanistically, BIA and select analogues markedly suppressed AKT phosphorylation and NLRP3 expression in lungs and airway epithelial cells. Pharmacological inhibition and TMBIM6 knockdown supported the involvement of the TMBIM6/AKT/NLRP3 signalling axis, while BIA and select analogues inhibited TMBIM6‐mediated ER calcium leakage. Conclusions and Implications: BIA and its analogues attenuate A. fumigatus ‐induced allergic lung inflammation by targeting the TMBIM6/calcium/AKT axis, suppressing NLRP3 signalling and epithelial‐derived inflammatory cytokines. These findings highlight this axis as a promising therapeutic target for fungal‐associated airway inflammation.
- 1 July 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (11) , 13827-13839
Synergistic Sedative Activity of Indirubin on Diazepam in Thiopental Sodium-induced Sleeping Mice: A Potential GABAergic Transmission
Insomnia remains one of the most common sleep disorders and causes significant discomfort as well as impairment in social, interpersonal, and vocational aspects of life. This study focuses on assessing the sedative activity of indigo naturalis indirubin (IND) on thiopental sodium (TS)-induced sleeping mice and evaluating the underlying molecular mechanisms through an in silico study. The adult male Swiss albino mice were used and given IND (5 and 10 mg/kg, i.p.), and diazepam (DZP) (2 mg/kg) in the respective groups individually and in combination to investigate modulatory effects. After 30 min, the treated mice were given TS (20 mg/kg, i.p.) to promote sleep, and the latency and duration of sleep were recorded manually. The in vivo study revealed that a higher dose of test sample (IND-10 mg/kg) showed lower latency and higher sleeping duration than a lower dose. Furthermore, an in silico study was performed to predict the involvement of gamma-aminobutyric acid (GABA) receptors in the sleep mechanism and assess pharmacokinetics and toxicity. Findings revealed that IND increased the duration of sleeping and decreased the latency of sleep induction. Additionally. the combination therapy of IND and DZP demonstrated synergistic sedative activity, as indicated by a greater reduction in locomotor activity and increased duration of sedation compared to either drug alone. IND exhibited a higher binding affinity (–9.1 kcal/mol) than DZP (–8.3 kcal/mol) at the identical binding site in the in silico study. The pharmacokinetic analysis of IND indicated acceptable drug-likeness and good pharmacokinetic properties. In conclusion, IND produced a potent sedative effect in the mouse model, possibly through the GABAA receptor interaction pathways.
- 1 July 2025
- Published by Springer Nature in Molecular Neurobiology
- Vol. 62 (11) , 13827-13839
Synergistic Sedative Activity of Indirubin on Diazepam in Thiopental Sodium-induced Sleeping Mice: A Potential GABAergic Transmission
Insomnia remains one of the most common sleep disorders and causes significant discomfort as well as impairment in social, interpersonal, and vocational aspects of life. This study focuses on assessing the sedative activity of indigo naturalis indirubin (IND) on thiopental sodium (TS)-induced sleeping mice and evaluating the underlying molecular mechanisms through an in silico study. The adult male Swiss albino mice were used and given IND (5 and 10 mg/kg, i.p.), and diazepam (DZP) (2 mg/kg) in the respective groups individually and in combination to investigate modulatory effects. After 30 min, the treated mice were given TS (20 mg/kg, i.p.) to promote sleep, and the latency and duration of sleep were recorded manually. The in vivo study revealed that a higher dose of test sample (IND-10 mg/kg) showed lower latency and higher sleeping duration than a lower dose. Furthermore, an in silico study was performed to predict the involvement of gamma-aminobutyric acid (GABA) receptors in the sleep mechanism and assess pharmacokinetics and toxicity. Findings revealed that IND increased the duration of sleeping and decreased the latency of sleep induction. Additionally. the combination therapy of IND and DZP demonstrated synergistic sedative activity, as indicated by a greater reduction in locomotor activity and increased duration of sedation compared to either drug alone. IND exhibited a higher binding affinity (–9.1 kcal/mol) than DZP (–8.3 kcal/mol) at the identical binding site in the in silico study. The pharmacokinetic analysis of IND indicated acceptable drug-likeness and good pharmacokinetic properties. In conclusion, IND produced a potent sedative effect in the mouse model, possibly through the GABAA receptor interaction pathways.
- 9 February 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (1) , e70064
Assessment of Antidiarrheal Effect of Oleuropein Through µ‐Oopioid Receptor Interaction Pathway: In Vivo and in Silico Studies
Oleuropein (OLP), a compound predominantly found in olive leaves, has been known for its numerous biological activities, including antioxidant, anti‐inflammatory, and antimicrobial properties. Despite its established therapeutic potential, its role in treating diarrhea has not been extensively explored. This study aimed to evaluate the antidiarrheal effects of OLP in an in vivo model and to investigate its molecular interactions using in silico docking studies, pharmacokinetic predictions, and toxicity analysis. In the in vivo study, castor oil was used to induce diarrhea in 3‐day‐old chicks, and the antidiarrheal effect of OLP was tested at doses of 10 and 20 mg/kg. The standard drug, loperamide (LOP) at 3 mg/kg, was used for comparison. The results showed that OLP at both doses significantly (p < 0.05) reduced diarrheal secretions and increased latency, with the 20 mg/kg dose demonstrating the most effective results. The combination of OLP (20 mg/kg) with LOP (3 mg/kg) further enhanced the antidiarrheal effect. In the in silico study, molecular docking revealed that both OLP and LOP exhibited strong binding affinities (BAs) to the key receptor, μ‐opioid receptor associated with diarrhea, while OLP showed higher BA (‒8.9 kcal/mol) compared to LOP (‒8.7 kcal/mol). Pharmacokinetic analysis of OLP revealed favorable properties and toxicity studies revealed no acute toxicity, with an LD50 of 2000 mg/kg. In conclusion, the findings suggest that OLP possesses significant antidiarrheal potential both in vivo and through receptor interaction, positioning it as a promising natural therapeutic agent for managing diarrhea. Further studies are warranted to fully elucidate its mechanisms of action and clinical applicability.
- 9 February 2025
- Published by Wiley in Drug Development Research
- Vol. 86 (1) , e70064
Assessment of Antidiarrheal Effect of Oleuropein Through µ‐Oopioid Receptor Interaction Pathway: In Vivo and in Silico Studies
Oleuropein (OLP), a compound predominantly found in olive leaves, has been known for its numerous biological activities, including antioxidant, anti‐inflammatory, and antimicrobial properties. Despite its established therapeutic potential, its role in treating diarrhea has not been extensively explored. This study aimed to evaluate the antidiarrheal effects of OLP in an in vivo model and to investigate its molecular interactions using in silico docking studies, pharmacokinetic predictions, and toxicity analysis. In the in vivo study, castor oil was used to induce diarrhea in 3‐day‐old chicks, and the antidiarrheal effect of OLP was tested at doses of 10 and 20 mg/kg. The standard drug, loperamide (LOP) at 3 mg/kg, was used for comparison. The results showed that OLP at both doses significantly (p < 0.05) reduced diarrheal secretions and increased latency, with the 20 mg/kg dose demonstrating the most effective results. The combination of OLP (20 mg/kg) with LOP (3 mg/kg) further enhanced the antidiarrheal effect. In the in silico study, molecular docking revealed that both OLP and LOP exhibited strong binding affinities (BAs) to the key receptor, μ‐opioid receptor associated with diarrhea, while OLP showed higher BA (‒8.9 kcal/mol) compared to LOP (‒8.7 kcal/mol). Pharmacokinetic analysis of OLP revealed favorable properties and toxicity studies revealed no acute toxicity, with an LD50 of 2000 mg/kg. In conclusion, the findings suggest that OLP possesses significant antidiarrheal potential both in vivo and through receptor interaction, positioning it as a promising natural therapeutic agent for managing diarrhea. Further studies are warranted to fully elucidate its mechanisms of action and clinical applicability.
- 5 December 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (8) , e70028
Anxiolytic Effect of Sesamol, Possibly Through the GABAkine Interaction Pathway
Plant‐based components have helped generate novel lead molecules and scaffolds for anxiety research in psychopharmacology. The present study examined the anxiolytic properties of sesamol (SES), a phenolic lignan derived from Sesamum indicum, employing both in vivo and computational methods to understand its mechanisms of action. In this experiment, adult Swiss albino mice received various doses of SES (25 and 50 mg/kg, p.o.) orally. Afterward, a series of behavioral assessments, including open field, swing, hole cross, and light–dark testing, were conducted. The impact of the GABAergic agonist diazepam (DZP‐1 mg/kg, i.p.) along with the antagonist flumazenil (FLU‐0.1 mg/kg, i.p.) has been studied as provided concurrently with the SES‐50 group. Computational studies were performed to comprehend the interaction between SES and GABAA receptor subunits (α2 and α3). The results of our investigation revealed that SES dose‐dependently and significantly (p < 0.05) reduced the number of square crosses, hole crosses, swings, grooming, and rearing along with a reduction of light residence time in animals. When combined with DZP, SES‐50 significantly reduced all these parameters, while altering with FLU‐0.1. The molecular docking analysis showed that the SES has a relatively good binding score (−5.03 ± 0.15 and −5.25 ± 0.23 kcal/mol) with GABAA receptor α2 and α3 subunits, respectively. The SES triggers anxiolytic effects via GABAA receptor α2 and α3 subunit interactions. Furthermore, precise and comprehensive preclinical research must be considered to validate potential SES targets for anxiolytic impact, clinical trial efficacy, and safety.
- 5 December 2024
- Published by Wiley in Drug Development Research
- Vol. 85 (8) , e70028
Anxiolytic Effect of Sesamol, Possibly Through the GABAkine Interaction Pathway
Plant‐based components have helped generate novel lead molecules and scaffolds for anxiety research in psychopharmacology. The present study examined the anxiolytic properties of sesamol (SES), a phenolic lignan derived from Sesamum indicum, employing both in vivo and computational methods to understand its mechanisms of action. In this experiment, adult Swiss albino mice received various doses of SES (25 and 50 mg/kg, p.o.) orally. Afterward, a series of behavioral assessments, including open field, swing, hole cross, and light–dark testing, were conducted. The impact of the GABAergic agonist diazepam (DZP‐1 mg/kg, i.p.) along with the antagonist flumazenil (FLU‐0.1 mg/kg, i.p.) has been studied as provided concurrently with the SES‐50 group. Computational studies were performed to comprehend the interaction between SES and GABAA receptor subunits (α2 and α3). The results of our investigation revealed that SES dose‐dependently and significantly (p < 0.05) reduced the number of square crosses, hole crosses, swings, grooming, and rearing along with a reduction of light residence time in animals. When combined with DZP, SES‐50 significantly reduced all these parameters, while altering with FLU‐0.1. The molecular docking analysis showed that the SES has a relatively good binding score (−5.03 ± 0.15 and −5.25 ± 0.23 kcal/mol) with GABAA receptor α2 and α3 subunits, respectively. The SES triggers anxiolytic effects via GABAA receptor α2 and α3 subunit interactions. Furthermore, precise and comprehensive preclinical research must be considered to validate potential SES targets for anxiolytic impact, clinical trial efficacy, and safety.
- 30 September 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (37)
Modulatory Sedative Activity of Abrine on Diazepam in Thiopental Sodium Mediated Sleeping Mice: An In Vivo Approach with Receptor Binding Affinity of GABAergic Transmission
The current study aims to assess the effects of abrine (ABR) in thiopental sodium (TS)‐induced sleeping mice and to explore the sedative impacts of the compound by using in vivo and in silico investigations. ABR (5 and 10 mg k −1 g, i.p.) and diazepam (DZP) (2 mg k −1 g, i.p.) were administered to the experimental animals either single or combined. TS (20 mg k −1 g, i.p.) was administered to induce sleep, and latency with sleeping duration was observed for 3 h. The in silico investigation was conducted to predict the role of ABR in the gamma‐aminobutyric acid A (GABA A ) receptor in the sleeping process and to evaluate pharmacokinetics and toxicity. Results showed that ABR (10 mg k −1 g) significantly ( p < 0.05) decreased the latency period (8.20 ± 1.85 min) and enhanced sleep duration (187.8 ± 8.87 min) in comparison with the control group. Additionally, the co‐treatments of ABR and DZP remarkably reduced the latency period (4.40 ± 0.24 min) and increased the sleeping duration (201.40 ± 5.89 min) compared to the single therapy. The molecular docking indicated that ABR has a binding affinity of −7.4 kcal/mol for the GABA A receptor. In conclusion, ABR provides strong sedative and synergistic efficacy on TS‐induced sleeping mice via the GABAergic system.
- 30 September 2024
- Published by Wiley in ChemistrySelect
- Vol. 9 (37)
Modulatory Sedative Activity of Abrine on Diazepam in Thiopental Sodium Mediated Sleeping Mice: An In Vivo Approach with Receptor Binding Affinity of GABAergic Transmission
The current study aims to assess the effects of abrine (ABR) in thiopental sodium (TS)‐induced sleeping mice and to explore the sedative impacts of the compound by using in vivo and in silico investigations. ABR (5 and 10 mg k −1 g, i.p.) and diazepam (DZP) (2 mg k −1 g, i.p.) were administered to the experimental animals either single or combined. TS (20 mg k −1 g, i.p.) was administered to induce sleep, and latency with sleeping duration was observed for 3 h. The in silico investigation was conducted to predict the role of ABR in the gamma‐aminobutyric acid A (GABA A ) receptor in the sleeping process and to evaluate pharmacokinetics and toxicity. Results showed that ABR (10 mg k −1 g) significantly ( p < 0.05) decreased the latency period (8.20 ± 1.85 min) and enhanced sleep duration (187.8 ± 8.87 min) in comparison with the control group. Additionally, the co‐treatments of ABR and DZP remarkably reduced the latency period (4.40 ± 0.24 min) and increased the sleeping duration (201.40 ± 5.89 min) compared to the single therapy. The molecular docking indicated that ABR has a binding affinity of −7.4 kcal/mol for the GABA A receptor. In conclusion, ABR provides strong sedative and synergistic efficacy on TS‐induced sleeping mice via the GABAergic system.
- 4 September 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (3) , 1-15
Sedative Effects of Daidzin, Possibly Through the GABAA Receptor Interaction Pathway: In Vivo Approach with Molecular Dynamic Simulations
The soy isoflavone daidzin (DZN) has been considered a hopeful bioactive compound having diverse biological activities, including anxiolytic, memory-enhancing, and antiepileptic effects, in experimental animals. However, its sedative and hypnotic effects are yet to be discovered. This study aimed to evaluate its sedative/hypnotic effect on Swiss mice. Additionally, in silico studies were also performed to see the possible molecular mechanisms behind the tested neurological effect. For this, male Swiss albino mice were treated with DZN (5, 10, or 20 mg/kg) intraperitoneally (i.p.) with or without the standard GABAergic medication diazepam (DZP) and/or flumazenil (FLU) and checked for the onset and duration of sleeping time using thiopental sodium-induced as well as DZP-induced sleeping tests. A molecular docking study was also performed to check its interaction capacity with the α1 and β2 subunits of the GABAA receptor. Findings suggest that DZN dose-dependently and significantly reduced the latency while increasing the duration of sleep in animals. In combination therapy, DZN shows synergistic effects with the DZP-2 and DZP-2 + FLU-0.01 groups, resulting in significantly (p < 0.05) reduced latency and increased sleep duration. Further, molecular docking studies demonstrate that DZN has a strong binding affinity of − 7.2 kcal/mol, which is closer to the standard ligand DZP (− 8.3 kcal/mol) against the GABAA (6X3X) receptor. Molecular dynamic simulations indicated stability and similar binding locations for DZP and DZN with 6X3X. In conclusion, DZN shows sedative effects on Swiss mice, possibly through the GABAA receptor interaction pathway.
- 4 September 2024
- Published by Springer Nature in Journal of Molecular Neuroscience
- Vol. 74 (3) , 1-15
Sedative Effects of Daidzin, Possibly Through the GABAA Receptor Interaction Pathway: In Vivo Approach with Molecular Dynamic Simulations
The soy isoflavone daidzin (DZN) has been considered a hopeful bioactive compound having diverse biological activities, including anxiolytic, memory-enhancing, and antiepileptic effects, in experimental animals. However, its sedative and hypnotic effects are yet to be discovered. This study aimed to evaluate its sedative/hypnotic effect on Swiss mice. Additionally, in silico studies were also performed to see the possible molecular mechanisms behind the tested neurological effect. For this, male Swiss albino mice were treated with DZN (5, 10, or 20 mg/kg) intraperitoneally (i.p.) with or without the standard GABAergic medication diazepam (DZP) and/or flumazenil (FLU) and checked for the onset and duration of sleeping time using thiopental sodium-induced as well as DZP-induced sleeping tests. A molecular docking study was also performed to check its interaction capacity with the α1 and β2 subunits of the GABAA receptor. Findings suggest that DZN dose-dependently and significantly reduced the latency while increasing the duration of sleep in animals. In combination therapy, DZN shows synergistic effects with the DZP-2 and DZP-2 + FLU-0.01 groups, resulting in significantly (p < 0.05) reduced latency and increased sleep duration. Further, molecular docking studies demonstrate that DZN has a strong binding affinity of − 7.2 kcal/mol, which is closer to the standard ligand DZP (− 8.3 kcal/mol) against the GABAA (6X3X) receptor. Molecular dynamic simulations indicated stability and similar binding locations for DZP and DZN with 6X3X. In conclusion, DZN shows sedative effects on Swiss mice, possibly through the GABAA receptor interaction pathway.
- Open Access
- 14 June 2024
- Published by Elsevier in Pharmaceutical Science Advances
- Vol. 2
Possible hemoglobin enhancing effect of phytol in methotrexate-induced folate deficient Swiss albino mice: In vivo and in silico studies
- 14 June 2024
- Published by Elsevier in Pharmaceutical Science Advances
- Vol. 2
Open AccessPossible hemoglobin enhancing effect of phytol in methotrexate-induced folate deficient Swiss albino mice: In vivo and in silico studies
- 27 February 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (5) , 2198-2214
Quercetin increases the antidepressant‐like effects of sclareol and antagonizes diazepam in thiopental sodium‐induced sleeping mice: A possible GABAergic transmission intervention
Quercetin is the most common polyphenolic flavonoid present in fruits and vegetables demonstrating versatile health‐promoting effects. This study aimed to examine the effects of quercetin (QR) and sclareol (SCL) on the thiopental sodium (TS)‐induced sleeping and forced swimming test (FST) mouse models. SCL (1, 5, and 10 mg/kg, p.o.) or QR (50 mg/kg, p.o.) and/or diazepam (DZP) (3 mg/kg, i.p.) were employed. After 30 min of TS induction, individual or combined effects on the animals were checked. In the FST test, the animals were subjected to forced swimming after 30 min of administration of the test and/or controls for 5 min. In this case, immobility time was measured. In silico studies were conducted to evaluate the involvement of GABA receptors. SCL (5 and 10 mg/kg) significantly increased the latency and decreased sleeping time compared to the control in the TS‐induced sleeping time study. DZP (3 mg/kg) showed a sedative‐like effect in animals in both sleeping and FST studies. QR (50 mg/kg) exhibited a similar pattern of activity as SCL. However, its effects were more prominent than those of SCL groups. SCL (10 mg/kg) altered the DZP‐3‐mediated effects. SCL‐10 co‐treated with QR‐50 significantly (p < 0.05) increased the latency and decreased sleep time and immobility time, suggesting possible synergistic antidepressant‐like effects. In silico studies revealed that SCL and QR demonstrated better binding affinities with GABAA receptor, especially α2, α3, and α5 subunits. Both compounds also exhibited good ADMET and drug‐like properties. In animal studies, the both compounds worked synergistically to provide antidepressant‐like effects in a slightly different fashion. As a conclusion, the combined administration of SCL and QR may be used in upcoming neurological clinical trials, according to in vivo and in silico findings. However, additional investigation is necessary to verify this behavior and clarify the potential mechanism of action.
- 27 February 2024
- Published by Wiley in Phytotherapy Research
- Vol. 38 (5) , 2198-2214
Quercetin increases the antidepressant‐like effects of sclareol and antagonizes diazepam in thiopental sodium‐induced sleeping mice: A possible GABAergic transmission intervention
Quercetin is the most common polyphenolic flavonoid present in fruits and vegetables demonstrating versatile health‐promoting effects. This study aimed to examine the effects of quercetin (QR) and sclareol (SCL) on the thiopental sodium (TS)‐induced sleeping and forced swimming test (FST) mouse models. SCL (1, 5, and 10 mg/kg, p.o.) or QR (50 mg/kg, p.o.) and/or diazepam (DZP) (3 mg/kg, i.p.) were employed. After 30 min of TS induction, individual or combined effects on the animals were checked. In the FST test, the animals were subjected to forced swimming after 30 min of administration of the test and/or controls for 5 min. In this case, immobility time was measured. In silico studies were conducted to evaluate the involvement of GABA receptors. SCL (5 and 10 mg/kg) significantly increased the latency and decreased sleeping time compared to the control in the TS‐induced sleeping time study. DZP (3 mg/kg) showed a sedative‐like effect in animals in both sleeping and FST studies. QR (50 mg/kg) exhibited a similar pattern of activity as SCL. However, its effects were more prominent than those of SCL groups. SCL (10 mg/kg) altered the DZP‐3‐mediated effects. SCL‐10 co‐treated with QR‐50 significantly (p < 0.05) increased the latency and decreased sleep time and immobility time, suggesting possible synergistic antidepressant‐like effects. In silico studies revealed that SCL and QR demonstrated better binding affinities with GABAA receptor, especially α2, α3, and α5 subunits. Both compounds also exhibited good ADMET and drug‐like properties. In animal studies, the both compounds worked synergistically to provide antidepressant‐like effects in a slightly different fashion. As a conclusion, the combined administration of SCL and QR may be used in upcoming neurological clinical trials, according to in vivo and in silico findings. However, additional investigation is necessary to verify this behavior and clarify the potential mechanism of action.